Maurizio Cantore - Concepedia

Author

Maurizio Cantore

Accademia di Belle Arti di Carrara ORCID

Also Known As

Cantore, Maurizio, M Cantore, M Gallo, M. Cantore, MAURIZIO CANTORE, Maurizio Cantore

178

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Accademia di Belle Arti di Carrara Istituti di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Carlo Poma University of Verona Ospedale San Giuseppe

About

Maurizio Cantore is an author at Accademia di Belle Arti di Carrara specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	28	1K
2	Health Sciences	10	12	449
3	Gastroenterology	6	7	324
4	Education	1	1	35
5	Cell Biology	1	1	26

Maurizio Cantore

Publications

Citations

H-Index

Page 1

	Year	Citations
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo, Annals of Oncology Surgical OncologyOncologyGastrointestinal OncologyMedicineFolinic Acid	2014	89
Pet therapy effects on oncological day hospital patients undergoing chemotherapy treatment. Massimo Orlandi, Karina Trangeled, Andrea Mambrini, PubMed	2008	85
Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer Maurizio Cantore, Carla Rabbi, G. Fiorentini, Oncology	2004	77
<scp><i>TERT</i></scp> gene harbors multiple variants associated with pancreatic cancer susceptibility Daniele Campa, Cosmeri Rizzato, Rachael Z. Stolzenberg‐Solomon, International Journal of Cancer	2015	76
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5‐fluorouracil in patients with unresectable biliary tract tumors Maurizio Cantore, Andrea Mambrini, Giammaria Fiorentini, Cancer	2005	74
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma Maurizio Cantore, R. Girelli, Andrea Mambrini, British journal of surgery	2012	68
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study Roberto Buzzoni, Sara Pusceddu, Emilio Bajetta, Annals of Oncology MedicineCancer ManagementBiliary CancerPathologyCancer Treatment	2014	68
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial Alberto Sobrero, Sara Lonardi, Gerardo Rosati, Journal of Clinical Oncology Surgical OncologyItalian ThreeGastroenterologyPathologyPharmacotherapy	2018	67
Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium Daniele Campa, Cosmeri Rizzato, Gabriele Capurso, Digestive and Liver Disease Functional CharacterisationPancreatic CancerGeneticsGenetic SusceptibilityGenetic Epidemiology	2012	62
GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III Christophe Louvet, Roberto Labianca, Pascal Hammel, Journal of Clinical Oncology Surgical OncologyPathologyPharmacotherapyGemox CombinationGemox Arm	2004	57

Page 1